What is the evidence for using omega-3 fatty acid formulas in ARDS?

• A. They have proven substantial mortality benefit in ARDS
• B. They should never be used due to toxicity
• C. Guidelines in 2009 recommended anti-inflammatory lipid enteral formulas; 2011 studies showed no improvement
• D. They are only beneficial in non-ARDS ICU patients

Answer: (C)

The main idea is that the evidence for omega-3 fatty acid formulas in ARDS has a mixed, evolving history. In 2009, guidelines suggested considering anti-inflammatory lipid enteral formulas for ARDS, reflecting early belief that EPA/DHA-containing feeds could dampen lung inflammation. By 2011, several studies did not show a clear improvement in important outcomes such as mortality or ventilator-free days, so the initial supportive stance did not translate into proven clinical benefit. This combination— guideline-based consideration early on, followed by later trials showing no meaningful improvement—best fits the statement that guidelines in 2009 recommended anti-inflammatory lipid formulas, but 2011 studies found no improvement. It’s not about toxicity, and it isn’t restricted to non-ARDS ICU patients; the issue is the lack of demonstrated benefit in ARDS across more robust evidence.